Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer
NCT ID: NCT02085564
Last Updated: 2015-06-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
87 participants
Study Classification
OBSERVATIONAL
Study Start Date
2014-03-31
Study Completion Date
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
The prevalence of gastroesophageal-junction cancer (cancer between the distal part of the oesophagus, and proximal part of the stomach/GEJ-cancer) is increasing in Denmark with more than 400 patients per year. The 5-year overall survival is less than 10% for the 2/3 of the patients, which are not considered resectable. Even for the 1/3, which is treated with surgical intervention and neoadjuvant chemotherapy the overall-survival is approximately 30%.
The current Danish intended curative treatment consists of esophagectomy (surgical resection of the oesophagus with extended lymphadenectomy in abdomen and thorax (removal of lymphnodes)). Furthermore, perioperative chemotherapy consists of 6 series neoadjuvant chemotherapy (3 series before, and 3 series after operation).
Unresectable patients receive palliative chemotherapy and no resection. Peritoneal washing cytology (PWC) is a recommended prediagnostic modality in gastric cancer patients. The method is used to detect free peritoneal cancer cells in the abdominal cavity even when macroscopic carcinomatosis is not present (i.e. the cancer has spread to other parts of the abdomen).
Carcinomatosis can be found in up to 19% in gastric cancer patients often in the peritoneum. Positive peritoneal cytology (C1) can be identified in up to 7% of gastric cancer patients without metastases (C1M0), i.e. malignant cells can be identified in the peritoneal washing, but tumor spread has not been identified.
Lots of studies indicate that C1-disease is an independent prognostic predictor for decreased survival, and increased recurrence rate, comparable with M1 patients (i.e. patients with distant metastases).
The American Joint Committee on cancer recommends that C1 patients should be treated non-surgically - even when M1 disease has not been identified.
On the basis of the above, PWC can be used to identify patients at greater risk for recurrence, and thereby not candidates for intended curative treatment.
It is a fact, though, that C1M0 patients have a better survival than C1M1 patients. Currently, there is no level-1 evidence for specific treatment of C1M0 patients, why further research is required to approach this patient group in the most comprehensive way. The focus group of our study is therefore C1M0 patients, because of the difference in opinions. Furthermore most evidence is based on gastric carcinomas, why GEJ-cancer patients are the group, we will examine.
Purpose:
Peritoneal washing cytology (PWC) is performed as a standard prediagnostic modality at Rigshospitalet, for patients with gastric- and GEJ cancer, considered resectable at preceding multidisciplinary conference. Most studies in the past 20-years have focused on gastric cancer, and not specifically GEJ-cancer.
This study will determine the usefulness of peritoneal washing cytology, and thereby verifying our own standard regarding GEJ-cancer. Furthermore, we will determine the effect of neoadjuvant chemotherapy on free peritoneal tumor cells and its correlation with overall survival.
This study is intended as a validation of our own standard.
The prevalence of gastroesophageal-junction cancer (cancer between the distal part of the oesophagus, and proximal part of the stomach/GEJ-cancer) is increasing in Denmark with more than 400 patients per year. The 5-year overall survival is less than 10% for the 2/3 of the patients, which are not considered resectable. Even for the 1/3, which is treated with surgical intervention and neoadjuvant chemotherapy the overall-survival is approximately 30%.
The current Danish intended curative treatment consists of esophagectomy (surgical resection of the oesophagus with extended lymphadenectomy in abdomen and thorax (removal of lymphnodes)). Furthermore, perioperative chemotherapy consists of 6 series neoadjuvant chemotherapy (3 series before, and 3 series after operation).
Unresectable patients receive palliative chemotherapy and no resection. Peritoneal washing cytology (PWC) is a recommended prediagnostic modality in gastric cancer patients. The method is used to detect free peritoneal cancer cells in the abdominal cavity even when macroscopic carcinomatosis is not present (i.e. the cancer has spread to other parts of the abdomen).
Carcinomatosis can be found in up to 19% in gastric cancer patients often in the peritoneum. Positive peritoneal cytology (C1) can be identified in up to 7% of gastric cancer patients without metastases (C1M0), i.e. malignant cells can be identified in the peritoneal washing, but tumor spread has not been identified.
Lots of studies indicate that C1-disease is an independent prognostic predictor for decreased survival, and increased recurrence rate, comparable with M1 patients (i.e. patients with distant metastases).
The American Joint Committee on cancer recommends that C1 patients should be treated non-surgically - even when M1 disease has not been identified.
On the basis of the above, PWC can be used to identify patients at greater risk for recurrence, and thereby not candidates for intended curative treatment.
It is a fact, though, that C1M0 patients have a better survival than C1M1 patients. Currently, there is no level-1 evidence for specific treatment of C1M0 patients, why further research is required to approach this patient group in the most comprehensive way. The focus group of our study is therefore C1M0 patients, because of the difference in opinions. Furthermore most evidence is based on gastric carcinomas, why GEJ-cancer patients are the group, we will examine.
Purpose:
Peritoneal washing cytology (PWC) is performed as a standard prediagnostic modality at Rigshospitalet, for patients with gastric- and GEJ cancer, considered resectable at preceding multidisciplinary conference. Most studies in the past 20-years have focused on gastric cancer, and not specifically GEJ-cancer.
This study will determine the usefulness of peritoneal washing cytology, and thereby verifying our own standard regarding GEJ-cancer. Furthermore, we will determine the effect of neoadjuvant chemotherapy on free peritoneal tumor cells and its correlation with overall survival.
This study is intended as a validation of our own standard.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy
NCT05561907
Gastric Outlet Obstruction
RECRUITING
NA
Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer
NCT03909997
Gastric Cancer
Esophagogastric Junction Disorder
UNKNOWN
Pilot Study of Stomach Cancer Early Detection and Prevention With Endoscopy
NCT05566899
Gastric Cancer
UNKNOWN
NA
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
NCT05450835
Gastric Cancer
RECRUITING
NA
Endoscopic Submucosal Dissection Versus Gastrectomy
NCT02216110
Early Gastric Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Background:
The prevalence of gastroesophageal-junction cancer is increasing in Denmark with more than 400 patients per year. The 5-year overall survival is less than 10% for the 2/3 of the patients, which are not considered resectable. Even for the 1/3, which is treated with surgical intervention and neoadjuvant chemotherapy, the overall-survival is approximately 30%.
The current Danish intended curative treatment consist of esophagectomy a.m. Ivor Lewis with extended lymphadenectomy in the abdomen and thorax. Furthermore, perioperative chemotherapy consists of 6 series neoadjuvant chemotherapy.
Unresectable patients receive palliative chemotherapy and no resection.
Peritoneal washing cytology is a recommended prediagnostic modality in gastric cancer. The method is used to detect free peritoneal cancer cells in the abdominal cavity, even when macroscopic carcinomatosis is not present.
Carcinomatosis can be found in up to 19% in gastric cancer patients, often in the peritoneum. Positive peritoneal cytology (C1) can be identified in up to 7% of gastric cancer patients without metastases (C1M0). Lots of studies indicate that C1-disease is an independent prognostic predictor for decreased survival, and increased recurrence rate, comparable with M1 patients (i.e. patients with distant metastases).
The American Joint Committee on cancer recommends that C1 patients should be treated non-surgically - even when M1 disease is not identified.
On the basis of the above, PWC can be used to identify patients at greater risk for recurrence, and thereby not candidates for intended curative treatment.
It is a fact, though, that C1M0 patients have a better survival than C1M1 patients. Currently, there is no level-1 evidence supporting specific treatment of C1M0 patients, why further research is required to approach this patient group in the most comprehensive way. Therefore, the focus group of our study is C1M0 patients, because of the differences in opinions. Furthermore, most evidence is based on gastric carcinomas, why GEJ-cancer patients are the group, we will examine.
Results from other investigators regarding treatment of C1M0 patients:
Lee et al. found a median survival of 21 months and 4 months in gastrectomized versus non-gastrectomized patients. Lorentzen et al. found a median 5-year survival of 71,4% and 25% in gastrectomized patients, who had C1 at staging laparoscopy and converted after preoperative chemotherapy versus persistent C1-disease after preoperative chemotherapy.
Another interesting treatment modality for C1M0 patients is extensive intraperitoneal lavage (EIPL) examined by a Japanese study group. 88 C1M0 patients were randomized into three group; 1. Gastrectomy only, 2. Gastrectomy + intraperitoneal chemotherapy (IPC), and 3. Gastrectomy + IPC + EIPL. Group 3 compared to group 2 had a significant better 5 year overall survival of 43,8% versus 4,6% (p\<0,0001).
Further research is required to establish specific guideline for C1M0 patients.
2. Purpose:
Peritoneal washing cytology (PWC) is performed as a standard prediagnostic modality at Rigshospitalet for patients, with gastric- and GEJ cancer, considered resectable at preceding multidisciplinary conference. Most studies in the past 20-years have focused on gastric cancer, and not specifically GEJ-cancer.
This study will determine the usefulness of peritoneal washing cytology, and thereby, verify our own standard regarding GEJ-cancer. Furthermore, we will determine the effect of neoadjuvant chemotherapy on free peritoneal tumor cells, correlated with overall survival.
See outcome measures for more detailed description. This study is intended as a validation of our own standard.
3. Methods
Our current algorithm includes peritoneal washings performed at two different time points:
A. Staging laparoscopy using one port technique
o After pneumoperitoneum and oversight of the abdomen is established, a puncture is created subhepatically in the midclavicular line with a pigtail catheter ch. 10.
* 500ml of sterile 37°C NaCl is injected through the catheter and manually dispersed throughout the abdomen by positioning the operating table in different positions.
* At least 200ml of fluid is aspirated subhepatically through the catheter.
* 100ml is analysed by an experienced pathologist for any malignant cancer cells.
B. Initially, before operation (transthoracic esophagectomy): either open operation or robot assisted o Robot assisted: same technique as above o Open operation: • After abdominal incision and exploration 500ml °C of sterile NaCl is manually dispersed in the abdominal cavity.
* Peritoneal washings is aspirated subhepatically
* Further algorithm as described above
4. Recruiting of patients:
90 consecutive patients with biopsy verified GEJ-cancer will be included. Because PWC is already a standard guideline for this group of patients at Rigshospitalet, there will be no direct inclusion of patients.
5\. Study design: Prospective feasibility study. Patients considered candidates for intented curative therapy, according to The Danish Esophagus-,GEJ- and Gastric Cancer Association (DECV), is included. Furthermore, patients must have undergone evaluation of a multidisciplinary panel of specialist including the specialties surgical gastroenterology, thoracic surgery, oncology, pathology, radiology, and clinical nuclear medicine.
6\. Data: Patient data will be obtained from internal systems of Rigshospitalet including OPUS, LABKA, PatologiWEB, and ORBIT.
The following preoperative data will be obtained:
\- age, sex, initial symptoms, tumour staging (TNM version 7) and histology characteristics, disease anamnesis, chemotherapy treatment, medicine anamnesis, comorbidity, postoperative complications, mortality, specifics regarding PWC such as injected volume of NaCl, procedure time, aspirated amount of fluid, and cytology findings.
7\. Approval: Authorization of data retreatment is approved by The Danish Data Protection Agency.
Approval of The Danish Ethics Committee has not been applied, because the study is a validation of our own standard guideline.
8\. Finances:
The following contributors have financed the study:
The Danish Cancer Society Research Center, Mogens Andreasen Fonden, Familien Erichsens familiefond, and Rigshospitalet.
All expenses have been covered.
9\. Results Both negative and positive results will be published in a national and/or international journal.
10\. Practical feasibility The relevant patients and the medical expertise are to find at the surgical gastroenterology department of Rigshospitalet. 120 staging laparoscopies are being performed per year in the handling of gastric cancer patients. Persons and departments involved in the study have agreed to allocate time and resources to the study. Furthermore, our department has a technician affiliated with our institution on full time basis, who is going to provide development, optimization, and assistance of projects associated with GEJ-cancer.
The prevalence of gastroesophageal-junction cancer is increasing in Denmark with more than 400 patients per year. The 5-year overall survival is less than 10% for the 2/3 of the patients, which are not considered resectable. Even for the 1/3, which is treated with surgical intervention and neoadjuvant chemotherapy, the overall-survival is approximately 30%.
The current Danish intended curative treatment consist of esophagectomy a.m. Ivor Lewis with extended lymphadenectomy in the abdomen and thorax. Furthermore, perioperative chemotherapy consists of 6 series neoadjuvant chemotherapy.
Unresectable patients receive palliative chemotherapy and no resection.
Peritoneal washing cytology is a recommended prediagnostic modality in gastric cancer. The method is used to detect free peritoneal cancer cells in the abdominal cavity, even when macroscopic carcinomatosis is not present.
Carcinomatosis can be found in up to 19% in gastric cancer patients, often in the peritoneum. Positive peritoneal cytology (C1) can be identified in up to 7% of gastric cancer patients without metastases (C1M0). Lots of studies indicate that C1-disease is an independent prognostic predictor for decreased survival, and increased recurrence rate, comparable with M1 patients (i.e. patients with distant metastases).
The American Joint Committee on cancer recommends that C1 patients should be treated non-surgically - even when M1 disease is not identified.
On the basis of the above, PWC can be used to identify patients at greater risk for recurrence, and thereby not candidates for intended curative treatment.
It is a fact, though, that C1M0 patients have a better survival than C1M1 patients. Currently, there is no level-1 evidence supporting specific treatment of C1M0 patients, why further research is required to approach this patient group in the most comprehensive way. Therefore, the focus group of our study is C1M0 patients, because of the differences in opinions. Furthermore, most evidence is based on gastric carcinomas, why GEJ-cancer patients are the group, we will examine.
Results from other investigators regarding treatment of C1M0 patients:
Lee et al. found a median survival of 21 months and 4 months in gastrectomized versus non-gastrectomized patients. Lorentzen et al. found a median 5-year survival of 71,4% and 25% in gastrectomized patients, who had C1 at staging laparoscopy and converted after preoperative chemotherapy versus persistent C1-disease after preoperative chemotherapy.
Another interesting treatment modality for C1M0 patients is extensive intraperitoneal lavage (EIPL) examined by a Japanese study group. 88 C1M0 patients were randomized into three group; 1. Gastrectomy only, 2. Gastrectomy + intraperitoneal chemotherapy (IPC), and 3. Gastrectomy + IPC + EIPL. Group 3 compared to group 2 had a significant better 5 year overall survival of 43,8% versus 4,6% (p\<0,0001).
Further research is required to establish specific guideline for C1M0 patients.
2. Purpose:
Peritoneal washing cytology (PWC) is performed as a standard prediagnostic modality at Rigshospitalet for patients, with gastric- and GEJ cancer, considered resectable at preceding multidisciplinary conference. Most studies in the past 20-years have focused on gastric cancer, and not specifically GEJ-cancer.
This study will determine the usefulness of peritoneal washing cytology, and thereby, verify our own standard regarding GEJ-cancer. Furthermore, we will determine the effect of neoadjuvant chemotherapy on free peritoneal tumor cells, correlated with overall survival.
See outcome measures for more detailed description. This study is intended as a validation of our own standard.
3. Methods
Our current algorithm includes peritoneal washings performed at two different time points:
A. Staging laparoscopy using one port technique
o After pneumoperitoneum and oversight of the abdomen is established, a puncture is created subhepatically in the midclavicular line with a pigtail catheter ch. 10.
* 500ml of sterile 37°C NaCl is injected through the catheter and manually dispersed throughout the abdomen by positioning the operating table in different positions.
* At least 200ml of fluid is aspirated subhepatically through the catheter.
* 100ml is analysed by an experienced pathologist for any malignant cancer cells.
B. Initially, before operation (transthoracic esophagectomy): either open operation or robot assisted o Robot assisted: same technique as above o Open operation: • After abdominal incision and exploration 500ml °C of sterile NaCl is manually dispersed in the abdominal cavity.
* Peritoneal washings is aspirated subhepatically
* Further algorithm as described above
4. Recruiting of patients:
90 consecutive patients with biopsy verified GEJ-cancer will be included. Because PWC is already a standard guideline for this group of patients at Rigshospitalet, there will be no direct inclusion of patients.
5\. Study design: Prospective feasibility study. Patients considered candidates for intented curative therapy, according to The Danish Esophagus-,GEJ- and Gastric Cancer Association (DECV), is included. Furthermore, patients must have undergone evaluation of a multidisciplinary panel of specialist including the specialties surgical gastroenterology, thoracic surgery, oncology, pathology, radiology, and clinical nuclear medicine.
6\. Data: Patient data will be obtained from internal systems of Rigshospitalet including OPUS, LABKA, PatologiWEB, and ORBIT.
The following preoperative data will be obtained:
\- age, sex, initial symptoms, tumour staging (TNM version 7) and histology characteristics, disease anamnesis, chemotherapy treatment, medicine anamnesis, comorbidity, postoperative complications, mortality, specifics regarding PWC such as injected volume of NaCl, procedure time, aspirated amount of fluid, and cytology findings.
7\. Approval: Authorization of data retreatment is approved by The Danish Data Protection Agency.
Approval of The Danish Ethics Committee has not been applied, because the study is a validation of our own standard guideline.
8\. Finances:
The following contributors have financed the study:
The Danish Cancer Society Research Center, Mogens Andreasen Fonden, Familien Erichsens familiefond, and Rigshospitalet.
All expenses have been covered.
9\. Results Both negative and positive results will be published in a national and/or international journal.
10\. Practical feasibility The relevant patients and the medical expertise are to find at the surgical gastroenterology department of Rigshospitalet. 120 staging laparoscopies are being performed per year in the handling of gastric cancer patients. Persons and departments involved in the study have agreed to allocate time and resources to the study. Furthermore, our department has a technician affiliated with our institution on full time basis, who is going to provide development, optimization, and assistance of projects associated with GEJ-cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Gastroesophageal-junction Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GEJ-cancer patients consideres resectable
All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
Peritoneal washing cytology
Intervention Type
PROCEDURE
The methode is describes in the detailed study description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peritoneal washing cytology
The methode is describes in the detailed study description
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Peritoneal lavage
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with biopsy verified GEJ-cancer referred to the department of surgical gastroenterology, Rigshospitalet, which is considered resectable at MDT-conference.
* \>18 years old
* informed consent
* \>18 years old
* informed consent
Exclusion Criteria
* \< 18 years old
* Not informed consent
* Not informed consent
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Cancer Society
OTHER
Sponsor Role
collaborator
Rigshospitalet, Denmark
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rune Broni Strandby
Junior researcher
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Bo Svendsen, Prof., MD., DMSc.
Role: STUDY_DIRECTOR
Department of surgical gastroenterology, Rigshospitalet
Michael Patrick Achiam, MD. phD.
Role: STUDY_CHAIR
Department of surgical gastroenterology, Rigshospitalet
Rune Broni Strandby, Junior researcher
Role: PRINCIPAL_INVESTIGATOR
Department of surgical gastroenterology, Rigshospitalet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of surgical gastroenterology, Rigshospitalet
Copenhagen, Kbh Ø, Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
050314-Rstrandby1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
NCT06243757
ACTIVE_NOT_RECRUITING
Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
NCT06728891
RECRUITING
Prophylactic EUS-guided Gastroenterostomy in Advanced Periampullary Cancers
NCT05994521
RECRUITING
NA
Gastric Partitioning Procedure for the Treatment of Unresectable and Obstructive Distal Gastric Cancer
NCT02064803
COMPLETED
NA
EUS-guided Versus Laparoscopic Gastrojejunostomy for Malignant Gastric Outlet Obstruction
NCT05605327
UNKNOWN
NA
G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through
NCT06068127
RECRUITING
Endoscopic Ultrasound and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers
NCT02324023
COMPLETED
NA
Quantitative Fluorescent Guided Robotic Surgery for Cancer of the Gastroesophageal Junction
NCT04107623
COMPLETED
NA
Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC
NCT07295002
NOT_YET_RECRUITING
NA
Endoscopic Ultrasound-guided Versus Surgical Gastroenterostomy for Malignant Gastric Outlet Obstruction
NCT05564143
UNKNOWN
NA
Evaluation of the Reliability of the Determination of MisMatch Repair Deficiency Status by Endoscopic Biopsies in Oesophagus and Gastric Adenocarcinoma.
NCT04774367
NOT_YET_RECRUITING
NA
Endoscopic Gastroenterostomy Versus Surgical Gastrojejunostomy
NCT06567691
ENROLLING_BY_INVITATION
NA
Endoscopic Unroofing for Small Gastric SETs
NCT02587923
UNKNOWN
SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up
NCT04613570
RECRUITING
NA
Retrospective Review of Gastrointestinal System Endoscopy Procedures
NCT05012527
COMPLETED
Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
NCT03857737
NOT_YET_RECRUITING
NA
Endoscopic Surveillance on a High-risk Population for Gastric Cancer in Latin America: The ECHOS Cohort Study.
NCT05969444
COMPLETED
Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China
NCT06869356
COMPLETED
Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia
NCT01384201
COMPLETED
PG Versus TG for Advanced PGC
NCT06614439
COMPLETED
NA
Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer
NCT02325999
UNKNOWN
EARLY_PHASE1
Application of OE in Diagnosis of EGC
NCT04720521
UNKNOWN
NA
A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy
NCT05829213
UNKNOWN
NA